Ipamorelin: Evidence, Safety, Dosing and Access

Ipamorelin is a peptide growth-hormone secretagogue and selective ghrelin-receptor agonist, also known as NNC 26-0161. Human evidence includes two randomized controlled trials, but the record is limited and does not prove broad anti-aging, fat-loss, or athletic-performance benefits. This article does not identify any FDA-approved ipamorelin product or FDA-approved wellness indication. Chia does not offer ipamorelin.

What it is

Ipamorelin is a peptide growth-hormone secretagogue, which means it is designed to signal the body’s growth-hormone system rather than replace growth hormone itself. In the supplied evidence, it is also called NNC 26-0161 and is described as a selective growth-hormone secretagogue 3.

Its drug class is a selective ghrelin-receptor agonist, sometimes called a ghrelin mimetic. In plain English, it acts on the growth hormone secretagogue receptor 1a, or GHSR-1a, a receptor involved in growth-hormone release 2, 3.

There is no established brand name in the supplied evidence. The generic or INN name is ipamorelin. Human trials in the retrieved record focused on pharmacology in human volunteers and postoperative ileus after bowel resection, not routine anti-aging care 2, 1.

Mechanism of action

Ipamorelin works through ghrelin-receptor signaling, especially the growth hormone secretagogue receptor 1a, or GHSR-1a. Human pharmacology research describes ipamorelin as a growth-hormone releasing peptide in volunteers, while earlier research describes it as selective within this secretagogue class 2, 3.

Ghrelin-receptor agonism and growth-hormone signaling

Ghrelin is a hormone-like signal that can affect appetite and growth-hormone pathways. Ipamorelin is described as a ghrelin mimetic, meaning it imitates part of ghrelin’s receptor activity rather than being ghrelin itself 1, 3.

The growth-hormone pathway often leads people to ask about IGF-1, body composition, and recovery. Those are plausible questions, but a plausible pathway is not the same as a proven clinical benefit; the available human randomized trials did not establish broad body-composition, performance, or longevity outcomes 2, 6.

What mechanism data can and cannot prove

Mechanism data can show that a compound touches a pathway. It cannot, by itself, prove that a person will lose fat, gain muscle, recover faster, or live longer. Reviews of peptide use in orthopaedics, sports medicine, and performance settings caution that evidence and safety vary by compound and use case 4, 5, 6.

Some ghrelin-mimetic research is preclinical. For example, animal research has evaluated ghrelin-receptor agonists, including ipamorelin, in pain and weight-loss models, but animal findings should not be presented as proven human outcomes 7, 12.

Evidence

Ipamorelin has an evidence grade of A under the rubric below because the retrieved PubMed set includes two human randomized controlled trials 2, 1. That grade tells us about study quantity and design; it does not mean ipamorelin works for every claimed use or is safe for every person.

What the two human randomized trials studied

One human randomized study modeled pharmacokinetics and pharmacodynamics of ipamorelin as a growth-hormone releasing peptide in human volunteers 2. Pharmacokinetics means how a compound moves through the body; pharmacodynamics means what it does to the body.

Another randomized, controlled, proof-of-concept study evaluated the ghrelin mimetic ipamorelin for postoperative ileus in bowel resection patients 1. Postoperative ileus means the bowel is slow to restart after surgery. This is a medical-surgery endpoint, not a wellness endpoint.

ClinicalTrials.gov also lists completed phase 2 studies of ipamorelin for recovery of gastrointestinal function and postoperative ileus, including studies with listed enrollments of 320 and 117 participants 10, 11. Trial registry listings help map what has been studied, but they do not replace full peer-reviewed results.

Why this evidence should not be stretched into anti-aging or body-composition claims

The human randomized trials in the retrieved set do not establish ipamorelin for longevity, belly-fat reduction, bodybuilding, or general wellness. Sports medicine and peptide reviews describe wide interest in peptide therapies but also stress that evidence, safety, and use cases differ across compounds 6, 8, 9.

That distinction matters. A compound can affect growth-hormone signaling and still lack strong human evidence for the outcome a person wants. Individual results vary, and unsupported performance claims deserve extra caution 6, 9.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-08.

Reported dosing ranges

Ipamorelin dosing should be viewed only as study context here, not as patient instructions. The retrieved source list confirms human pharmacology and postoperative-ileus trials, but the supplied record metadata does not provide a usable published dose range to reproduce safely 2, 1.

Study-dose context versus patient dosing

A study dose is chosen for a protocol, a population, and an endpoint. It is not a personal plan. The human studies named above focused on pharmacology and surgical bowel recovery, so they should not be converted into dosing advice for wellness, body composition, or performance 2, 1.

Why this article should not be used as a dosing guide

This page does not tell you how much ipamorelin to use, when to use it, or how to combine it with other peptides. That kind of decision requires a clinician who can review your health history, medications, labs when needed, and treatment goals.

Legal status

Our regulatory log holds no confirmed federal action for Ipamorelin. That means we have not found one with a primary source — not that none exists.

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-08. See the full legal-status tracker for every compound we follow.

Safety

Ipamorelin safety data in the retrieved human evidence is limited by the specific settings studied: human volunteers and bowel resection patients, not long-term wellness use 2, 1. A short-term trial can miss rare events, delayed effects, and risks that appear only with repeated or combined use.

What human trials can tell us about short-term safety

The human volunteer study helps describe exposure-response relationships for ipamorelin as a growth-hormone releasing peptide 2. The bowel resection trial helps describe use in a postoperative clinical setting 1. Together, they are useful, but they do not create a complete safety profile for every patient group.

Because ipamorelin works through growth-hormone signaling, clinicians think carefully about conditions where growth-hormone or IGF-1 pathway changes could matter. The retrieved studies do not provide enough long-term data to say how these pathway effects translate across broad populations 2, 6.

What remains unknown about long-term use

Long-term use for longevity, fat loss, muscle gain, or recovery is not established by the human randomized trials in the supplied record. Reviews of peptide therapies note that evidence and safety questions vary by compound and that unapproved or supplement-style peptide use can outpace the clinical evidence 5, 6, 8.

Unknowns include long-term endocrine effects, effects in people with complex medical histories, risks with multiple peptides, and product-quality risks when a substance is bought outside medical care. Sterility, identity, and impurity problems are especially important with injectable or nasal products that are not dispensed through a licensed clinical process.

Why sports, bodybuilding, and performance claims need extra caution

Sports and bodybuilding discussions often move faster than the evidence. Reviews of peptide and peptide-analog drug use in recreational and professional sport describe concerns around performance claims, doping, and variable evidence quality 9, 6.

If a claim sounds simple, such as “ipamorelin burns belly fat” or “ipamorelin builds muscle,” the honest answer is that the retrieved human randomized evidence does not prove those outcomes. For a broader safety overview, our guide to peptide side effects explains why the source, route, and clinician oversight matter.

Interactions

Ipamorelin interaction studies are not established in the retrieved evidence set. That is not reassurance; it means the published material supplied here does not give a complete drug-interaction map.

Growth-hormone and IGF-1 pathway considerations

Because ipamorelin is studied as a growth-hormone releasing peptide, interaction questions should include medications and conditions that affect endocrine signaling, glucose metabolism, fluid balance, and cancer history. The retrieved human studies do not answer these questions for broad wellness use 2, 1.

Reviews in sports medicine and endocrine-aesthetic peptide use discuss therapeutic peptides across several settings, but review-level discussion should not be treated as proof of safety for a specific person or peptide stack 6, 13.

When clinician review is especially important

• If you have a history of cancer, pituitary disease, endocrine disease, diabetes, or unexplained swelling, because growth-hormone and IGF-1 pathway questions may be clinically important 2, 6.
• If you use multiple peptides, hormones, anabolic agents, or bodybuilding compounds, because combination-specific human trials are not established in the supplied evidence 6, 9.
• If you are recovering from surgery or have gastrointestinal disease, because the human postoperative-ileus evidence is tied to specific surgical settings and should not be generalized without medical review 1.
• If a product is labeled “research use only,” because that label does not describe clinician-supervised medical care or state-licensed pharmacy dispensing.

How to obtain it legally

Ipamorelin is not offered by Chia. We do not prescribe, compound, ship, or sell ipamorelin. We include it in our peptide library because patients ask about it, and an honest answer should separate human evidence from wellness marketing.

Clinician evaluation, documentation, and pharmacy quality questions

A safer medical process starts with a clinician evaluation, not a product page. A clinician should review your goals, conditions, medications, prior labs when relevant, and whether a peptide pathway makes sense for you. A prescription, when clinically appropriate, is never guaranteed.

If a clinician-supervised treatment is appropriate, medication quality should be part of the discussion. Useful questions include who evaluates you, what pharmacy dispenses the medication, whether the pharmacy is state-licensed, and how sterility, identity, and potency are handled. Our guide to finding a legitimate peptide source covers those questions in more detail.

Why research-chemical vendors are not the same as medical care

A research-chemical website is not the same as a licensed provider visit. It does not replace medical screening, diagnosis, documentation, adverse-event monitoring, or pharmacy quality controls. Our article on research-only peptides versus prescription access explains why that distinction matters for patients.

What Chia offers instead for related peptide and longevity goals

At Chia, we do offer related longevity treatments, but not ipamorelin. For growth-hormone-axis goals, our providers may evaluate eligible patients for sermorelin, which Chia offers as injection, nasal spray, and tablets. Sermorelin plans currently start at $179/mo for injections.

For broader longevity support, Chia also offers NAD+ and glutathione, including the Foundation Longevity protocol, which combines Sermorelin Injection, NAD+ Injection, and Glutathione Injection and currently starts at $399/mo. Treatment at Chia is 100% online: a short health questionnaire is reviewed by a licensed US provider, prescriptions are written only where clinically appropriate, and medications are compounded by state-licensed US 503A pharmacies and shipped to the patient’s door. Compounded medications are not FDA-approved.

If you are comparing ipamorelin with sermorelin, start with evidence and safety rather than forum advice. Our guide to CJC-1295/ipamorelin versus sermorelin and our deeper article on sermorelin peptide therapy explain the differences in plain language.

Ipamorelin FAQ

Keep reading

Peptides

CJC-1295 and Ipamorelin Dosage Calculator: What Online Tools Can and Cannot Tell You

Peptides

Can You Buy IGF-1 LR3? What Patients Should Know Before Ordering

Peptides

Sermorelin Dosage and Reddit Advice: What Patients Should Know